Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02411123 · ClinicalTrials.gov registry record · NA
Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Subjects Exhibiting Neuropsychiatric Disorders
A NA study of Depression and Anxiety, sponsored by AltheaDx.
- Completed
- Registry status
- NA
- Development phase
- 220
- Enrollment target
- 1
- Study location
NCT02411123: Completed NA study of Depression and Anxiety, sponsored by AltheaDx.
NCT02411123 is a NA study of Depression and Anxiety that has completed, run by AltheaDx. The registered enrollment target is 220 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02411123, a NA study of Depression and Anxiety, has completed, sponsored by AltheaDx.
- COMPLETED
- Registry status
- NA
- Development phase
- 220 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effect of pharmacogenetic (PGx) testing on clinical outcomes in a group of subjects exhibiting neuropsychiatric disorders, such as depression and anxiety, as compared to a group of subjects with the same attributes without the guidance of PGx testing for their treatment. This study will also evaluate whether pharmacogenetic (PGx) testing can reduce adverse drug events, hospitalization rates, hospital length of stay, emergency room visits, disability, death or other serious drug side effects.
Primary Outcome
Neuropsychiatric Questionnaire (NPQ) score change comparison between the two treatment arms over a 4-month period.
Conditions Studied
Interventions
- GENETIC IDgenetix Neuropsychiatric Test Panel
Study Locations (1)
North Carolina
- Carolina Partners in Mental HealthCare - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2015-03 |
| Est. Completion | 2015-12 |
| Phase | NA |
What the finished NCT02411123 record still lists
NCT02411123 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (72% lower).
The record links to 2 conditions, with Depression appearing as the primary indexed condition, and to 1 intervention - of which IDgenetix Neuropsychiatric Test Panel is the first listed.
NCT02411123 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT02411123 about?
NCT02411123 is a clinical study titled "Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Subjects Exhibiting Neuropsychiatric Disorders". The purpose of this study is to evaluate the effect of pharmacogenetic (PGx) testing on clinical outcomes in a group of subjects exhibiting neuropsychiatric disorders, such as depression and anxiety, as compared to a group of subjects with the same attributes without the guidance of PGx testing for ...
What is the current status of trial NCT02411123?
This trial is currently completed. It is a NA study. The enrollment target is 220 participants. The study started on 2015-03. Estimated completion is 2015-12.
What conditions does trial NCT02411123 study?
This clinical trial studies the following conditions: Depression, Anxiety.
What interventions are being tested in trial NCT02411123?
The interventions under investigation include: IDgenetix Neuropsychiatric Test Panel (GENETIC).
Who is sponsoring clinical trial NCT02411123?
This trial is sponsored by AltheaDx, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02411123 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02411123's enrollment target sits among peer trials
220 196th of 679 higher than 483 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
Cold and Heat Investigation to Lower Levels of Depression
RECRUITING · NA
-
Dosing rTMS for Depression Post-SCI
RECRUITING · NA
-
Exploring Virtual Reality Adventure Training Exergaming
RECRUITING · NA
-
Brief Interventions for Coping with Distress
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia